Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each
Hopes of a treatment for Alzheimer’s disease have been dealt another blow by the failure of an experimental drug to slow the progression of the condition in global clinical trials.
The Swiss pharmaceutical firm Roche said its drug, gantenerumab, showed no clear benefit in twin trials which explored its impact on memory, problem solving and other cognitive skills in people with early stage Alzheimer’s.
